Edward Cha
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 23
- Cancer Immunotherapy and Biomarkers 20
- Pancreatic and Hepatic Oncology Research 2
-
- Hepatocellular Carcinoma Treatment and Prognosis 4
- Co-authors
- Lawrence H. Fong (6 shared papers)Christopher Y. Park (1 shared paper)Suzanne Li (1 shared paper)Craig A. Cummings (1 shared paper)Yafei Hou (1 shared paper)Antoni Ribas (1 shared paper)Mark Klinger (1 shared paper)Malek Faham (1 shared paper)
- Journals
- Annals of Oncology (6 papers)The Lancet Oncology (3 papers)ESMO Open (2 papers)The Oncologist (2 papers)OncoImmunology (2 papers)
- Partner nations
- United StatesSouth KoreaChina
In The Last Decade
Edward Cha
39 papers receiving 2.3k citations
Edward Cha's Hit Papers
Peers
Comparison fields: 5 of 68
- Oncology 1.2k
- Hepatology 371
- Immunology 370
- Pulmonary and Respiratory Medicine 197
- Molecular Biology 300
Countries citing papers authored by Edward Cha
This map shows the geographic impact of Edward Cha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Cha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Cha more than expected).
Fields of papers citing papers by Edward Cha
This network shows the impact of papers produced by Edward Cha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Cha. The network helps show where Edward Cha may publish in the future.
Co-authors
The 25 scholars most cited alongside Edward Cha, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 374 |
| 2 | 2014 | 339 | |
| 3 | 2000 | 330 | |
| 4 | 2020 | 239 | |
| 5 | 2019 | 200 | |
| 6 | 2019 | 146 | |
| 7 | 2017 | 57 | |
| 8 | 2008 | 54 | |
| 9 | 2023 | 49 | |
| 10 | Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study Hit paper breakdown → | 2025 | 48 |
| 11 | 2012 | 46 | |
| 12 | 2011 | 42 | |
| 13 | 2015 | 42 | |
| 14 | 2012 | 36 | |
| 15 | 2020 | 35 | |
| 16 | 2016 | 31 | |
| 17 | 2023 | 31 | |
| 18 | 2015 | 30 | |
| 19 | 2021 | 30 | |
| 20 | 2015 | 28 |
About Edward Cha
Edward Cha is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Immunology and Molecular Biology, having authored 40 papers that have together received 2.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (20 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Melanoma and MAPK Pathways (4 papers), Lung Cancer Treatments and Mutations (3 papers), Esophageal Cancer Research and Treatment (3 papers), Prostate Cancer Treatment and Research (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Microbial Inactivation Methods (1 paper). The work is most often cited by research in Oncology (1.2k citations), Hepatology (371 citations), Immunology (370 citations), Pulmonary and Respiratory Medicine (197 citations) and Molecular Biology (300 citations). Edward Cha has collaborated with scholars based in United States, South Korea and China. Frequent co-authors include Lawrence H. Fong, Christopher Y. Park, Suzanne Li, Craig A. Cummings, Yafei Hou, Antoni Ribas, Mark Klinger, Malek Faham, ADIL I. DAUD and Serena S. Kwek. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, ESMO Open, The Oncologist and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.